The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer
Open accessAbstract
Purpose: Gonadotropin-releasing hormone (GnRH) agonists decrease bone mineral density, a surrogate for fracture risk, in men with prostate cancer. We conducted a claims-based cohort study to characterize the relationship between GnRH agonists and risk for clinical fractures in men with nonmetastatic prostate cancer. Patients and Methods: Using medical claims data from a 5% national random sample of Medicare beneficiaries, we identified a study group of men with nonmetastatic prostate cancer who initiated GnRH agonist treatment from 1992 to 1994 (n = 3,887). A comparison group of men with nonmetastatic prostate cancer who did not receive GnRH agonist treatment during the study period (n = 7,774) was matched for age, race, geographic location, and comorbidity. Clinical fractures were identified using inpatient, outpatient, and physician claims during 7 years of follow-up. Results: In men with nonmetastatic prostate cancer, GnRH agonists significantly increased fracture risk. The rate of any clinical fracture was 7.88 per 100 person-years at risk in men receiving a GnRH agonist compared with 6.51 per 100 person-years in matched controls (relative risk, 1.21; 95% CI, 1.14 to 1.29; P < .001). Rates of vertebral fractures (relative risk, 1.45; 95% CI, 1.19 to 1.75; P < .001) and hip/femur fractures (relative risk, 1.30; 95% CI, 1.10 to 1.53; P = .002) were also significantly higher in men who received a GnRH agonist. GnRH agonist treatment independently predicted fracture risk in multivariate analyses. Longer duration of treatment conferred greater fracture risk. Conclusion: GnRH agonists significantly increase risk for any clinical fracture, hip fractures, and vertebral fractures in men with prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Use of Inhaled Corticosteroids and Risk of Fractures
Van Staa, T. P., Leufkens, H. G. M., & Cooper, C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,308
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
The crippling consequences of fractures and their impact on quality of life
Cooper, C. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)90022-x · Cited by 699
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
Self-citation(1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.d01-6840.x · Cited by 654
SMITH, M. R., EASTHAM, J., GLEASON, D. M., SHASHA, D., TCHEKMEDYIAN, S., & ZINNER, N. (2003) · Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650
Self-citationAdib, R., Anderson, J., Ashken, M. H., Baumber, C. D., CRA, B. D., BEYNON, L. L., Blaxland, J. W., Boag, V., Bolger, J., Boreham, J., et al. (1997) · Kent Academic Repository (University of Kent) · Cited by 551
Self-citationWeinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., Glendenning, G. A., & Schulman, K. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi122 · Cited by 362
Skeletal Fractures Negatively Correlate With Overall Survival in Men With Prostate Cancer
Oefelein, M. G., Ricchiuti, V., Conrad, W., & Resnick, M. I. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64561-2 · Cited by 347
RE: OSTEOPOROSIS AFTER ORCHIECTOMY FOR PROSTATE CANCER
Krongrad, A., Levis, S., & Roos, B. A. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64271-x · Cited by 339
Osteoporosis After Orchiectomy for Prostate Cancer
Daniell, H. W. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65165-6 · Cited by 315
MAILLEFERT, J. F., SIBILIA, J., MICHEL, F., SAUSSINE, C., JAVIER, R. M., & TAVERNIER, C. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61639-2 · Cited by 308
Townsend, M. F., Sanders, W. H., Northway, R. O., & Graham, S. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<545::aid-cncr17>3.0.co;2-3 · Cited by 260
Diamond, T. H., Higano, C. S., Smith, M. R., Guise, T. A., & Singer, F. R. (2004) · Cancer · doi:10.1002/cncr.20056 · Cited by 255
Self-citationSmith, M. R., Fallon, M. A., Lee, H., & Finkelstein, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032058 · Cited by 248
Self-citationDiamond, T., Campbell, J., Bryant, C., & Lynch, W. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981015)83:8<1561::aid-cncr11>3.0.co;2-z · Cited by 246
Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens
Eriksson, S., Eriksson, A., Stege, R., & Carlstr�m, K. (1995) · Calcified Tissue International · doi:10.1007/bf00298427 · Cited by 191
Diamond, T. H., Winters, J., Smith, A., De Souza, P., Kersley, J. H., Lynch, W. J., & Bryant, C. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6<1444::aid-cncr1468>3.0.co;2-m · Cited by 190
OEFELEIN, M. G., RICCHUITI, V., CONRAD, W., SEFTEL, A., BODNER, D., GOLDMAN, H., & RESNICK, M. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65661-3 · Cited by 188
Yao, S.-L., & Lu-Yao, G. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1950 · Cited by 166
Hatano, T., Oishi, Y., Furuta, A., Iwamuro, S., & Tashiro, K. (2000) · British Journal of Urology · doi:10.1046/j.1464-410x.2000.00774.x · Cited by 152
Fracture Risk Following Bilateral Orchiectomy
Melton, L. J., Alothman, K. I., Khosla, S., Achenbach, S. J., Oberg, A. L., & Zincke, H. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000059281.67667.97 · Cited by 136
Nejat, R. J., Rashid, H. H., Bagiella, E., Katz, A. E., & Benson, M. C. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)66910-8 · Cited by 122
Hip fracture in elderly men: prognostic factors and outcomes
DIAMOND, T. H., Thornley, S. W., Sekel, R., & Smerdely, P. (1997) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1997.tb126646.x · Cited by 119
Higano, C. S., Shields, A. T., Wood, N., Brown, J. E., & Tangen, C. M. (2004) · Urology · doi:10.1016/j.urology.2004.07.019 · Cited by 91
Trump, D. L. (2004) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2004.07.010 · Cited by 62
Bae, D. C., & Stein, B. S. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000141515.67372.e5 · Cited by 55
Steiner, M. S., Patterson, A., Israeli, R., Barnette, K. G., Boger, R. S., & Price, D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.4597 · Cited by 26
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Self-citationMohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Self-citationAdverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
Self-citationGalvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2488 · Cited by 657
Metadata
- Authors
- Smith, M. R., Lee, W. C., Brandman, J., Wang, Q., Botteman, M., & Pashos, C. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-11-01
- Volume
- 23
- Issue
- 31
- Pages
- 7897-7903
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162514583
- Cited by
- 366
- References
- 33
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.